Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅲ Study of Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

NCT01019616 is registered in ClinicalTrials.gov with Tao OUYANG as lead sponsor.

NCT NCT01019616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01019616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅲ Study of Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy
Lead sponsor
Tao OUYANG
Phase
Phase 3
Overall status
Unknown status
Start date
March 4, 2011
Completion date
June 30, 2022
Enrollment
400 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

primary breast cancer